Triglycerides, Diabetes and Cardiovascular Disease

甘油三酯、糖尿病和心血管疾病

• 批准号: 10642739
• 负责人: Karin E. Bornfeldt
• 金额: $ 239.02万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-15 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10642739
• 关键词: ANGPTL3 gene; Address; Affect; Apolipoproteins; Applications Grants; Area; Atherosclerosis; Cardiovascular Diseases; Chylomicrons; Complement; Complications of Diabetes Mellitus; Data; Development; Diabetes Mellitus; Diabetic Angiopathies; Doctor of Philosophy; Ensure; Fertilization; Generations; Genes; Glucose; Goals; Hepatic; High Density Lipoprotein Cholesterol; High Density Lipoproteins; Human; Hypertriglyceridemia; Impairment; Inflammatory; Insulin Resistance; Insulin-Dependent Diabetes Mellitus; Interruption; Investigation; Knowledge; LDL Cholesterol Lipoproteins; Lesion; Link; Lipids; Lipolysis; Lipoproteins; Low-Density Lipoproteins; Macrophage; Metabolic; Metabolic syndrome; Metabolism; Methods; Myeloid Cells; Nature; New York; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathogenesis; Pathway interactions; Patients; Phenotype; Phospholipid Transfer Proteins; Population; Prevention strategy; Production; Productivity; Program Research Project Grants; Prospective Studies; Proteins; Proteomics; Regulation; Research; Research Personnel; Residual state; Risk; Testing; Therapeutic Agents; Therapeutic Intervention; Triglyceride Metabolism; Triglycerides; Universities; Very low density lipoprotein; Washington; analytical tool; atherogenesis; atherosclerosis risk; cardiovascular disorder prevention; cardiovascular disorder risk; design; diabetic; diabetic cardiomyopathy; dyslipoproteinemia; effective intervention; fatty liver disease; glucose metabolism; insight; lipid metabolism; lipoprotein lipase; mouse model; non-diabetic; novel; novel therapeutics; particle; pharmacologic; premature; prevent; programs; synergism

The overall hypothesis of the Triglycerides, Diabetes and Cardiovascular Disease Program Project is that abnormal metabolism of triglyceride-rich lipoproteins driven by specific proteins—APOC3, ANGPTL3, PLTP, and LPL—promotes the accumulation of highly atherogenic remnant lipoprotein particles in patients with diabetes, even in those with normal triglyceride levels. Remnant lipoprotein particles and associated abnormalities in HDL contribute to cardiovascular disease risk by altering macrophage functions, thereby promoting atherogenesis and increasing cardiovascular disease risk in diabetes. We propose that the increased risk of cardiovascular disease (CVD) associated with diabetes can be understood, prevented, and treated only by increasing our knowledge of the factors that regulate triglyceride- rich lipoproteins (TRLs) and their remnant lipoprotein particles (RLPs) and associated macrophage phenotypes. TRLs and their remnants comprise a great variety of nascent and metabolically derived particles differing in size, protein composition, and lipid content, which has made it difficult to identify the mechanisms that promote atherosclerosis. We plan to address this complexity by focusing on specific pathways and proteins and by using unique analytical tools. We believe that a highly interactive and interdisciplinary group of investigators with extensive expertise in this area, such as ours, is needed to answer the question of how TRLs and RLPs promote CVD risk. The expertise of our team in different aspects pertaining to the overall hypotheses of this Program Project will ensure synergy and cross-fertilization between Projects, which is likely to markedly advance research in this important and timely area. Importantly, the RLPs and proteins that control them are amenable to therapeutic intervention. We therefore believe that our projects will provide new insights into the pathogenesis of CVD in diabetes and suggest new ways to target and prevent the increased CVD risk in this large population. The Program Project Grant consists of four Projects and three Core units:  Project 1: Diabetes, triglyceride-rich lipoproteins, and advanced atherosclerosis – Karin E. Bornfeldt, PhD, Project Leader  Project 2: Regulation of lipid and glucose metabolism by ANGPTL3 in humans – Nathan Stitziel, MD, PhD, Project Leader  Project 3: Lipolysis regulation and diabetes-impaired regression – Ira J. Goldberg, MD, Project Leader  Project 4: Lipoproteins and CVD risk in diabetes – Jay W. Heinecke, MD, Project Leader  Core A: Administrative Core – Karin E. Bornfeldt, PhD, Core Director  Core B: Proteomics and lipoprotein characterization core – Tomas Vaisar, PhD, Core Director  Core C: Myeloid cell and atherosclerosis core – Jenny E. Kanter, PhD, Core Director

甘油三酯、糖尿病和心血管疾病计划项目的总体假设是 由特定蛋白质——APOC3、ANGPTL3、驱动的富含甘油三酯的脂蛋白的异常代谢 PLTP 和 LPL——促进高度致动脉粥样硬化的残余脂蛋白颗粒在体内的积累 糖尿病患者，即使是甘油三酯水平正常的患者和残余脂蛋白颗粒。 HDL 相关异常通过改变巨噬细胞导致心血管疾病风险 功能，从而促进动脉粥样硬化形成并增加糖尿病患者的心血管疾病风险。 我们建议，与糖尿病相关的心血管疾病（CVD）风险增加可以 只有通过增加我们对调节甘油三酯的因素的了解，才能理解、预防和治疗。 富脂蛋白 (TRL) 及其残余脂蛋白颗粒 (RLP) 和相关巨噬细胞 TRL 及其残余物包含多种新生和代谢衍生的颗粒。 大小、蛋白质组成和脂质含量不同，这使得确定其机制变得困难 我们计划通过关注特定途径来解决这种复杂性。 我们相信，通过使用独特的分析工具，蛋白质是一个高度互动和跨学科的团队。 需要像我们这样在该领域拥有广泛专业知识的研究人员来回答 TRL 如何 我们团队在与整体相关的不同方面的专业知识会增加 CVD 风险。 该计划项目的假设将确保项目之间的协同作用和交叉促进，这很可能 显着推进这一重要且及时的领域的研究，重要的是控制 RLP 和蛋白质。 因此，我们相信我们的项目将提供新的见解。 研究糖尿病 CVD 的发病机制，并提出针对和预防 CVD 风险增加的新方法 在如此庞大的人口中，该计划项目补助金由四个项目和三个核心单位组成：  项目 1：糖尿病、富含甘油三酯的脂蛋白和晚期动脉粥样硬化 – Karin E. Bornfeldt， 博士，项目负责人  项目 2：ANGPTL3 对人类脂质和葡萄糖代谢的调节 – Nathan Stitziel，医学博士， 博士，项目负责人  项目 3：脂肪分解调节和糖尿病受损回归 – Ira J. Goldberg，医学博士，项目负责人  项目 4：糖尿病中的脂蛋白和 CVD 风险 – Jay W. Heinecke，医学博士，项目负责人  核心 A：行政核心 – Karin E. Bornfeldt 博士，核心总监  核心 B：蛋白质组学和脂蛋白表征核心 – Tomas Vaisar 博士，核心主任  核心 C：骨髓细胞和动脉粥样硬化核心 – Jenny E. Kanter 博士，核心主任

项目成果

ABCA1 is an extracellular phospholipid translocase.

ABCA1 是一种细胞外磷脂转位酶。

• DOI: 10.1038/s41467-022-32437-3
• 发表时间: 2022-08-16
• 期刊: Nature communications
• 影响因子: 16.6

Size matters: HDL particle populations and the risk of infection.

大小很重要：HDL 颗粒数量和感染风险。

• DOI: 10.1038/s41569-023-00844-8
• 发表时间: 2023
• 期刊: Nature reviews. Cardiology
• 作者: Heinecke,JayW;Davidson,WSean
• 通讯作者: Davidson,WSean

Addressing dyslipidemic risk beyond LDL-cholesterol.

• DOI: 10.1172/jci148559
• 发表时间: 2022-01-04
• 期刊: The Journal of clinical investigation
• 作者: Tall AR;Thomas DG;Gonzalez-Cabodevilla AG;Goldberg IJ
• 通讯作者: Goldberg IJ

Emerging Concepts of Vascular Cell Clonal Expansion in Atherosclerosis.

• DOI: 10.1161/atvbaha.121.316093
• 发表时间: 2022-03
• 期刊: Arteriosclerosis, thrombosis, and vascular biology
• 作者: Misra A;Rehan R;Lin A;Patel S;Fisher EA
• 通讯作者: Fisher EA